source
- RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo TherapeuticsRallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
- Croatian researcher’s five-decade quest to uncover BPC-157’s potential draws FDA attentionIn 1975 a second‑year medical student at the University of Zagreb heard a lecture on stress and the stomach lining. He imagined the organ produced a natural anti‑stress chemical and set out to find…